A successful pregnancy in a patient with Takayasu's arteritis under tocilizumab treatment: A longitudinal case study

A successful antenatal outcome in a patient with refractory Takayasu’s arteritis treated with tocilizumab throughout pregnancy—a case report

“…Relapsing, resistant TA poses significant challenges during pregnancy. Whilst biologics are discontinued prior to pregnancy or early in the first trimester; uncontrolled or flaring disease can put both the mother and foetus at risk of complications such as worsening hypertension, pre-eclampsia, prematurity and/or intra-uterine growth restriction [ 4 ]. High-dose glucocorticoids also contribute to BP dysregulation and impaired glucose tolerance, thus adding to overall pregnancy risks.…”

A Systematic Review of the safety of non-TNF inhibitor biologic and targeted synthetic drugs in rheumatic disease in pregnancy

“…Other small case-series [79] of 4 RA pregnancies (with n=3 live births all >37 weeks and n=1 miscarriage) and case reports [75][76][77][78] of 4 pregnancies, all resulted in full-term live births without complications, thus were reassuring.…”

“…A total of 11 studies including; 4 case reports [75][76][77][78], 3 case series [79][80][81] and 4 cohort studies [82][83][84][85] reported on 385 pregnancies (Table 1). Exposure to tocilizumab occurred: between 3 weeks to 15 months preconception (n=100); preconception and during first trimester (n=22); during first trimester (n=200); during second and third trimesters (n=21); from preconception and throughout pregnancy and breastfeeding (n=5); during breastfeeding only (n=4); and at unknown time-points (n=33).…”

Update on pregnancy in Takayasu arteritis—A narrative review

“…Tumor necrosis factor inhibitors are compatible during pregnancy as per the latest guidelines 42 . There is also one case report of active disease in pregnancy being treated successfully with IL‐6 blocker tocilizumab 52 . Certolizumab pegol was tried in three patients during pregnancy refractory to conventional therapy and was found effective in two patients in terms of laboratory and clinical remission and in one patient in terms of angiographic remission 53 …”